2
Clinical Trials associated with CARTmeso CART19(First Affiliated Hospital of Wenzhou Medical University)Single-center, Open-label, Single-arm Clinical Study of Efficacy and Safety of Anti-CD123 CAR-T Therapy in Patients With Refractory/Relapsed CD123+ Acute Myeloid Leukemia.
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of anti-CD123 CAR-T cells in patients with refractory/relapsed CD123+ Acute Myeloid Leukemia.
Pilot Study of Autologous Chimeric Antigen Receptor Cells Against Mesothelin and CD19 in Patients With Pancreatic Cancer
Pancreatic cancer patients receive chimeric antigen receptor (CAR) T cells against mesothelin (CARTmeso) or CD19 (CART19) cells administered at 3 days via pancreatic artery infusion or i.v. after preconditioning of cyclophosphamide. Both CART cells are autologous. CARTmeso cells target pancreatic cells which highly express mesothelin, while CART19 cells target tumor-associated B cells expressing cluster of differentiation antigen 19 (CD19) which are mostly immunosuppressive. The investigators hypothesize that this combination therapy may enhance the efficacy of CARTmeso cells in the body. Additionally, a medium dose of cyclophosphamide is used to enhance the engraftment of CART cells.
100 Clinical Results associated with CARTmeso CART19(First Affiliated Hospital of Wenzhou Medical University)
100 Translational Medicine associated with CARTmeso CART19(First Affiliated Hospital of Wenzhou Medical University)
100 Patents (Medical) associated with CARTmeso CART19(First Affiliated Hospital of Wenzhou Medical University)
100 Deals associated with CARTmeso CART19(First Affiliated Hospital of Wenzhou Medical University)